TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Company is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% year-over-year growth and approximately 12% sequential growth
80% confidenceOUS (outside U.S.) transplant revenue grew approximately 33% sequentially to $5 million in Q4 2025
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceTotal revenue for Q4 was approximately $161 million with U.S. transplant revenue at approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceLiver share gains are pure TransMedics execution excellence
80% confidenceTransMedics is laser-focused on ensuring successful execution of these initiatives throughout 2026
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceCompetitor in ENHANCE Part B trial (makers of styrofoam box) is refusing to randomize their technology against TransMedics
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceUpcoming registry publication will demonstrate unequivocal statistical superiority in the most important outcomes after liver transplantation
80% confidenceTransMedics achieved its best operational performance to date despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceTransMedics achieved our best operational performance to date with these results achieved despite external challenges earlier in the year that were designed to distract and disrupt our sustained and transformational growth
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceTransMedics is laser-focused on ensuring successful execution of 2026 initiatives
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though in early stages
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume, up from 26% in 2024, and OCS Heart comprised 18% of heart transplants, up from 17%
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidence